Kathleen Essel, MD, a fellow at University of Oklahoma Health Science Center, discusses the findings from a recent trial investigating the safety of long-term treatment with bevacizumab (Avastin) in patients with ovarian cancer.
Essel says the results from this trial can provide a lot of comfort, since patients who did well initially on this treatment subsequently did well later on. Findings demonstrated that adverse effects found during initial treatment did not worsen later on.
Interestingly, patients with an initial increase in blood pressure did not experience this adverse event in the long-term. Researchers were most concerned about cardiovascular effects or hypertension and were surprised to find bevacizumab was generally well tolerated as a long-term treatment in this patient population.
For more on the latest research and advances in ovarian cancer: [ Ссылка ]
